Clinical Trials Logo

Carcinoma, Non-Small-Cell Lung clinical trials

View clinical trials related to Carcinoma, Non-Small-Cell Lung.

Filter by:

NCT ID: NCT05639751 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Study of PRT3789 in Participants With Select Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Start date: January 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1 dose-escalation study of PRT3789, a SMARCA2 degrader, in participants with advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of PRT3789, describe any dose limiting toxicities (DLTs), define the dosing schedule, and to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) to be used in subsequent development of PRT3789.

NCT ID: NCT05638425 Recruiting - Brain Metastases Clinical Trials

Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain Metastases

Start date: December 31, 2021
Study type: Observational

This is a prospective, single-center observational clinical study aimed at the efficacy and safety of radiotherapy combined with PD-1 inhibitors and chemotherapy in the treatment of Chinese patients with symptomatic NSCLC with brain metastases.

NCT ID: NCT05637580 Completed - Clinical trials for Non Small Cell Lung Cancer

Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLC

Start date: May 20, 2019
Study type: Observational

This is a real-world study with the largest sample size investigating the pathological tumor and lymph node responses to neoadjuvant immunochemotherapy in non-small cell lung cancer to date. Patients with initially unresectable NSCLC underwent immunochemotherapy and response to treatment was assessed after every two treatment cycles. Clinicopathologic features of patients including epidemiological data, clinical manifestations, operation strategies, pathological findings, and prognostic information were recorded and evaluated.

NCT ID: NCT05635708 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Start date: March 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is structured as a master protocol with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) with high programmed cell death protein ligand-1 (PD-L1) expression (≥ 50%), and Sub-study 2 includes participants with NSCLC with low or negative (PD-L1) expression (< 50%).

NCT ID: NCT05634551 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

Perceptions on Expected Outcomes of Immunotherapy in Advanced Non-small Cell Lung Cancer Patients With Poor Performance Status

Start date: May 30, 2023
Study type: Observational

To better understand your feelings and expectations about immunotherapy

NCT ID: NCT05633602 Not yet recruiting - Clinical trials for Stage IV Lung Cancer AJCC v8

Ramucirumab Plus Pembrolizumab vs Standard Chemotherapy for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Start date: December 15, 2022
Phase: Phase 3
Study type: Interventional

This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy.

NCT ID: NCT05631574 Not yet recruiting - Colorectal Cancer Clinical Trials

Study of BMF-219 in Adult Patients With Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer.

Start date: December 2022
Phase: Phase 1
Study type: Interventional

A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort 2), and CRC (Cohort 3).

NCT ID: NCT05631249 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

Start date: November 21, 2022
Phase: Phase 2
Study type: Interventional

This study aims to provide a comprehensive understanding of sotorasib's mechanisms of action and resistance in NSCLC patients.

NCT ID: NCT05628376 Not yet recruiting - Clinical trials for Small Cell Lung Cancer

TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx) EVO

Start date: May 2023
Study type: Observational

TRACERx EVO is a programme of work using a prospective observational cohort study of participants with early- and late-stage non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

NCT ID: NCT05627960 Recruiting - Clinical trials for Non Small Cell Lung Cancer

First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

Start date: February 14, 2022
Phase: Phase 1
Study type: Interventional

This is a first in human phase 1 study of AG01 an anti-Progranulin/Glycoprotein88 (PGRN/GP88) antibody in patients with advanced solid tumors. AG01 is a recombinant monoclonal antibody expressed in a CHO production cell line. The antibody AG01 binds to human PGRN/GP88, expressed on cancer cells. This study will have a dose escalation portion (1A) to evaluate maximum tolerated dose (MTD) and/or maximum administered dose (MAD), the safety and tolerability of AG01treatment before the dose expansion portion (1B) of the study is initiated. The dose escalation portion of this study (1A) will also be used to determine the recommended phase 2 dose (RP2D) of AG01 antibody to be evaluated in the cohort expansion portion (1B).